2024-03-28 08:30 | UU:GILD | | News Release200 | FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six |
2024-03-28 07:00 | UU:GILD | | News Release200 | Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program |
2024-03-28 07:00 | UU:GILD | | News Release200 | Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program |
2024-03-26 09:18 | UU:GILD | | News Release200 | Winn Awards Help Physicians Solve Healthcare Disparities |
2024-03-22 09:18 | UU:GILD | | News Release200 | Gilead Sciences Announces Completion of Acquisition of CymaBay |
2024-03-19 09:08 | UU:GILD | | News Release200 | Gilead Helps Launch Turkiye's First HIV Testing Week |
2024-03-18 19:29 | UU:GILD | | News Release200 | Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant |
2024-03-12 08:47 | UU:GILD | | News Release200 | Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations |
2024-03-11 08:24 | UU:GILD | | News Release200 | Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer |
2024-03-07 08:17 | UU:GILD | | News Release200 | Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing |
2024-03-06 16:30 | UU:GILD | | News Release200 | Biktarvy(TM) Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities |
2024-03-06 10:25 | UU:GILD | | News Release200 | Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 |
2024-03-06 08:00 | UU:GILD | | News Release200 | Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers |
2024-03-05 16:35 | UU:GILD | | News Release200 | New Real-World Data Further Support the Use of Veklury(TM) (Remdesivir) for People Hospitalized With COVID-19 |
2024-03-05 16:30 | UU:GILD | | News Release200 | Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health |
2024-03-05 08:47 | UU:GILD | | News Release200 | Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area |
2024-02-29 08:33 | UU:GILD | | News Release200 | Gilead Sciences: National Black HIV/AIDS Awareness Day |
2024-02-28 17:17 | UU:GILD | | News Release200 | Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. |
2024-02-27 10:00 | UU:GILD | | News Release200 | Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. |
2024-02-26 16:05 | UU:GILD | | News Release200 | U.S. FDA Approves Expanded Indication for Gilead's Biktarvy(TM) to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance |
2024-02-26 08:30 | UU:GILD | | News Release200 | Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 |
2024-02-26 08:16 | UU:GILD | | News Release200 | Gilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change |
2024-02-20 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Present at Upcoming Investor Conferences |
2024-02-20 09:26 | UU:GILD | | News Release200 | Gilead Named One of America ¢ € ™s Most JUST Companies by JUST Capital and CNBC |
2024-02-13 08:33 | UU:GILD | | News Release200 | Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies |
2024-02-12 08:30 | UU:GILD | | News Release200 | Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics |
2024-02-09 11:00 | UU:GILD | | News Release200 | Gilead Named One of America ¢ € ™s Most JUST Companies by JUST Capital and CNBC |
2024-02-06 16:05 | UU:GILD | | News Release200 | Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend |
2024-02-06 16:02 | UU:GILD | | News Release200 | Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results |
2024-02-06 08:18 | UU:GILD | | News Release200 | Gilead Named One of Newsweek America ¢ € ™s Greatest Workplaces for Diversity |
2024-02-01 16:31 | UU:GILD | | News Release200 | Ted Love, MD, Joins Gilead Sciences ¢ € ™ Board of Directors |
2024-01-30 08:30 | UU:GILD | | News Release200 | Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta ‚ ® CAR T-cell Therapy |
2024-01-30 08:11 | UU:GILD | | News Release200 | From the Margins: Gilead ¢ € ™s Book Uniquely Captures What It ¢ € ™s Like To Be Marginalized by Disease |
2024-01-29 17:00 | UU:GILD | | News Release200 | Gilead and Arcus Announce Amended Collaboration and Equity Investment |
2024-01-29 17:00 | UU:GILD | | News Release200 | Gilead and Arcus Announce Amended Collaboration and Equity Investment |
2024-01-23 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024 |
2024-01-23 09:52 | UU:GILD | | News Release200 | Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer |
2024-01-22 08:30 | UU:GILD | | News Release200 | Gilead Provides Update on Phase 3 EVOKE-01 Study |
2024-01-17 08:46 | UU:GILD | | News Release200 | Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer |
2024-01-16 10:03 | UU:GILD | | News Release200 | Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer |
2024-01-10 11:13 | UU:GILD | | News Release200 | Gilead Pays Tribute to Patient Advocacy Work: Cara ¢ € ™s Story |
2024-01-03 11:18 | UU:GILD | | News Release200 | Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year |
2023-12-21 16:05 | UU:GILD | | News Release200 | U.S. FDA Approves Label Update for Kite ¢ € ™s Yescarta ‚ ® CAR T-Cell Therapy to Include Overall Survival Data |
2023-12-21 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Present at Upcoming Investor Conference |
2023-12-20 08:45 | UU:GILD | | News Release200 | RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola |
2023-12-19 08:16 | UU:GILD | | News Release200 | Gilead Supports World Health Organization To Bolster Public Health in Bangladesh |
2023-12-19 07:00 | UU:GILD | | News Release200 | Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program |
2023-12-12 13:40 | UU:GILD | | News Release200 | Gilead's Legal Team Achieves Rigorous Diversity Certification |
2023-12-12 08:11 | UU:GILD | | News Release200 | Gilead's Legal Team Achieves Rigorous Diversity Certification |
2023-12-11 21:00 | UU:GILD | | News Release200 | Analyses of Kite ¢ € ™s Yescarta ‚ ® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas |
2023-12-11 19:30 | UU:GILD | | News Release200 | New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite ¢ € ™s Tecartus ‚ ® in Patients With Aggressive Blood Cancers |
2023-12-11 17:45 | UU:GILD | | News Release200 | Long-Term Data for Kite ¢ € ™s Yescarta ‚ ® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma |
2023-12-11 12:00 | UU:GILD | | News Release200 | Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year |
2023-12-06 21:09 | UU:GILD | | News Release200 | Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023 |
2023-12-01 15:16 | UU:GILD | | News Release200 | Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt |
2023-11-30 08:30 | UU:GILD | | News Release200 | Gilead ¢ € ™s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023 |
2023-11-28 08:17 | UU:GILD | | News Release200 | Gilead's Ambition: To Help End the HIV Epidemic |
2023-11-21 08:26 | UU:GILD | | News Release200 | Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas |
2023-11-15 06:00 | UU:GILD | | News Release200 | Kite and Arcellx Announce Expansion in Strategic Partnership |
2023-11-15 06:00 | UU:GILD | | News Release200 | ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP |
2023-11-14 08:47 | UU:GILD | | News Release200 | Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS |
2023-11-09 09:01 | UU:GILD | | News Release200 | Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research |
2023-11-08 19:13 | UU:GILD | | News Release200 | Gilead Sciences to Present at Upcoming Investor Conferences |
2023-11-07 16:02 | UU:GILD | | News Release200 | Gilead Sciences Announces Third Quarter 2023 Financial Results |
2023-11-07 09:32 | UU:GILD | | News Release200 | Gilead Sciences: Advancing Global Health Equity in Tropical Regions |
2023-11-06 17:00 | UU:GILD | | News Release200 | Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers |
2023-11-06 17:00 | UU:GILD | | News Release200 | Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers |
2023-11-03 11:00 | UU:GILD | | News Release200 | Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting ‚ ® 2023 |
2023-11-02 09:15 | UU:GILD | | News Release200 | Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 |
2023-10-31 08:22 | UU:GILD | | News Release200 | Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic |
2023-10-31 07:30 | UU:GILD | | News Release200 | Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer |
2023-10-24 12:00 | UU:GILD | | News Release200 | Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS |
2023-10-20 05:10 | UU:GILD | | News Release200 | New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca ‚ ® for Adults With Multi-Drug Resistant HIV |
2023-10-19 03:00 | UU:GILD | | News Release200 | Real-World Evidence Reinforces Biktarvy ‚ ® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities |
2023-10-18 03:00 | UU:GILD | | News Release200 | Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program |
2023-10-17 09:32 | UU:GILD | | News Release200 | Gilead Sciences: Leading With Passion and Purpose: Sandra ¢ € ™s Story |
2023-10-17 07:00 | UU:GILD | | News Release200 | Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases |
2023-10-16 07:30 | UU:GILD | | News Release200 | Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023 |
2023-10-16 01:01 | UU:GILD | | News Release200 | Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023 |
2023-10-12 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 |
2023-10-12 09:00 | UU:GILD | | News Release200 | Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032 |
2023-10-03 08:30 | UU:GILD | | News Release200 | Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023 |
2023-10-02 09:00 | UU:GILD | | News Release200 | Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders |
2023-09-19 08:30 | UU:GILD | | News Release200 | CHMP Adopts Positive Opinion to Extend the Use of Veklury ‚ ® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment |
2023-09-18 04:00 | UU:GILD | | News Release200 | Kite ¢ € ™s Car T-cell Therapy Yescarta ‚ ® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma |
2023-09-10 03:01 | UU:GILD | | News Release200 | Gilead ¢ € ™s Phase 2 EVOKE-02 Study of Trodelvy ‚ ® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA ‚ ® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer |
2023-09-07 20:55 | UU:GILD | | News Release200 | Gilead Prices $2 Billion of Senior Unsecured Notes |
2023-09-07 11:52 | UU:GILD | | News Release200 | Gilead Sciences: How One School Has Transformed Education for First-Generation Students |
2023-08-30 08:47 | UU:GILD | | News Release200 | Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South |
2023-08-24 08:30 | UU:GILD | | News Release200 | FDA Approves Veklury ‚ ® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment |
2023-08-23 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Present at Upcoming Investor Conferences |
2023-08-23 08:46 | UU:GILD | | News Release200 | How Gilead ¢ € ™s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines |
2023-08-21 08:30 | UU:GILD | | News Release200 | Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML |
2023-08-18 12:00 | UU:GILD | | News Release200 | Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative ‚ ® on HIV in the Southern United States |
2023-08-16 08:02 | UU:GILD | | News Release200 | Gilead ¢ € ™s Focus on Ending the HIV Epidemic for Children Everywhere |
2023-08-15 08:30 | UU:GILD | | News Release200 | Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation |
2023-08-09 08:07 | UU:GILD | | News Release200 | Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV |
2023-08-03 16:02 | UU:GILD | | News Release200 | Gilead Sciences Announces Second Quarter 2023 Financial Results |
2023-08-02 13:59 | UU:GILD | | News Release200 | Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities |
2023-07-27 13:23 | UU:GILD | | News Release200 | European Commission Approves Gilead ¢ € ™s Trodelvy ‚ ® For Pre-Treated HR+/HER2- Metastatic Breast Cancer |
2023-07-24 19:00 | UU:GILD | | News Release200 | Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV |
2023-07-24 08:00 | UU:GILD | | News Release200 | Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million |
2023-07-23 21:51 | UU:GILD | | News Release200 | New Biktarvy ‚ ® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic |
2023-07-23 17:00 | UU:GILD | | News Release200 | Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities |
2023-07-21 17:02 | UU:GILD | | News Release200 | Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS |
2023-07-20 12:00 | UU:GILD | | News Release200 | Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S. |
2023-07-20 12:00 | UU:GILD | | News Release200 | Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States |
2023-07-20 12:00 | UU:GILD | | News Release200 | Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States |
2023-07-19 10:20 | UU:GILD | | News Release200 | Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth |
2023-07-19 08:30 | UU:GILD | | News Release200 | Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023 |
2023-07-14 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023 |
2023-07-14 08:00 | UU:GILD | | News Release200 | FDA Approves Veklury ‚ ® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis |
2023-07-13 06:00 | UU:GILD | | News Release200 | Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries |
2023-06-23 08:11 | UU:GILD | | News Release200 | Gilead Receives CHMP Positive Opinion for Trodelvy ‚ ® in Pre-Treated HR+/HER2- Metastatic Breast Cancer |
2023-06-23 02:30 | UU:GILD | | News Release200 | Hepcludex ‚ ® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks |
2023-06-22 08:30 | UU:GILD | | News Release200 | Kite Announces Completion of Marketing Authorization Transfer for Yescarta ‚ ® CAR T-cell Therapy in Japan |
2023-06-14 03:00 | UU:GILD | | News Release200 | Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023 |
2023-06-06 10:45 | UU:GILD | | News Release200 | Kite ¢ € ™s Tecartus ‚ ® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma |
2023-06-05 12:30 | UU:GILD | | News Release200 | Trodelvy ‚ ® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer |
2023-06-05 11:25 | UU:GILD | | News Release200 | Kite ¢ € ™s Yescarta ‚ ® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma |
2023-06-03 13:30 | UU:GILD | | News Release200 | Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study |
2023-06-01 08:34 | UU:GILD | | News Release200 | Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA |
2023-05-26 01:00 | UU:GILD | | News Release200 | CHMP Adopts Positive Opinion to Extend the Use of Veklury ‚ ® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis |
2023-05-25 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Present at Upcoming Investor Conference |
2023-05-17 08:30 | UU:GILD | | News Release200 | Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023 |
2023-05-16 16:01 | UU:GILD | | News Release200 | Gilead Appoints Cindy Perettie Executive Vice President of Kite |
2023-05-15 08:30 | UU:GILD | | News Release200 | Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation |
2023-05-15 08:30 | UU:GILD | | News Release200 | Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation |
2023-05-09 08:30 | UU:GILD | | News Release200 | Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera |
2023-05-04 07:00 | UU:GILD | | News Release200 | CHMP Adopts Positive Opinion Recommending Hepcludex ‚ ® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV) |
2023-05-01 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Present at Upcoming Investor Conferences |
2023-04-27 16:02 | UU:GILD | | News Release200 | Gilead Sciences Announces First Quarter 2023 Financial Results |
2023-04-16 04:00 | UU:GILD | | News Release200 | Veklury ‚ ® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations |
2023-04-13 16:05 | UU:GILD | | News Release200 | Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023 |